Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA

Fredrik H. Schjesvold*, Nicolaas A. Bakker, Pieter Sonneveld

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

7 Downloads (Pure)
Original languageEnglish
Article number101528
JournalTranslational Oncology
Volume25
DOIs
Publication statusPublished - Nov 2022

Bibliographical note

2022 The Authors. Published by Elsevier Inc.

Cite this